Vitiligo Clinical Trial
Official title:
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
Vitiligo is an autoimmune cutaneous disorder that destroys melanocytes leading to depigmented
areas of skin. In the United States, vitiligo affects 1% of patients, causing not only
changes in the color of skin, but also significant cosmetic concerns and quality of life
issues. Current treatment modalities, which include topical corticosteroids, intralesional
corticosteroids, phototherapy, and systemic immunosuppression, are variably effective in
inducing repigmentation. Unfortunately, some cases of vitiligo are refractory to treatment.
There is a need for new, effective modalities to treat patients with otherwise refractory
vitiligo.
Needling is an office based procedure that theoretically transposes healthy, pigmented skin
cells to depigmented areas using a needle in vitiligo patients. Two preliminary studies of
needling as a novel treatment for vitiligo had promising results but were limited by small
sample size and subjective results.
The proposed randomized control trial (RCT) will further investigate the use of needling to
treat vitiligo. It differs from the previous studies in that it seeks to identify the cause
of clinical benefit by comparing needling alone to needling with corticosteroid, examines a
larger number of patients, and quantifies improvement using confocal microscopy. Confocal
microscopy (CFM) allows non-invasive visualization of the skin on a cellular level and has
been used in the past to diagnose cutaneous pigmentary conditions. This study would be the
first RCT of needling in vitiligo to use an objective measure to quantify results, thus has
the potential to establish needling as a novel, effective treatment for vitiligo and to
evaluate the utility of CFM for monitoring response to treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
| Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
| Not yet recruiting |
NCT05927272 -
Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions
|
N/A | |
| Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
| Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
| Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
| Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
| Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
| Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
| Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
| Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
| Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
| Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
| Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
| Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
| Recruiting |
NCT05635266 -
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |